ALX Oncology (ALXO) to Post Quarterly Earnings on Tuesday

ALX Oncology (NASDAQ:ALXO) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect ALX Oncology to post earnings of ($0.15) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Friday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, analysts expect ALX Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ALX Oncology Stock Performance

NASDAQ:ALXO traded up $0.07 during mid-day trading on Tuesday, reaching $2.00. 172,738 shares of the stock were exchanged, compared to its average volume of 1,006,197. The stock has a market capitalization of $268.45 million, a P/E ratio of -1.34 and a beta of 0.42. ALX Oncology has a 1 year low of $0.56 and a 1 year high of $2.66. The company has a 50 day simple moving average of $1.87 and a 200-day simple moving average of $1.91. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in ALXO. Invesco Ltd. purchased a new stake in ALX Oncology during the 1st quarter valued at approximately $46,000. Bridgeway Capital Management LLC purchased a new position in shares of ALX Oncology in the 3rd quarter valued at approximately $66,000. AQR Capital Management LLC grew its stake in shares of ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after purchasing an additional 77,065 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of ALX Oncology in the second quarter valued at approximately $84,000. Finally, State Street Corp increased its holdings in shares of ALX Oncology by 11.0% in the fourth quarter. State Street Corp now owns 124,228 shares of the company’s stock valued at $140,000 after purchasing an additional 12,300 shares during the period. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ALXO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a report on Friday, June 26th. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.60.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.